Skip to main content

Table 4 Predictive factors for overall survival

From: Feasibility and efficacy of helical tomotherapy in cirrhotic patients with unresectable hepatocellular carcinoma

Factors Median survival (months) P value
Univariate analysis Multivariate analysis
Age (years)   0.821  
  ≤ 67 8.5 ± 5.5   
  > 67 7.2 ± 4.7   
Gender   0.225  
 Male 8.5 ± 6.2   
 Female 6.3 ± 2.8   
ECOG score   <0.001 0.012
 0–1 9.5 ± 7.2   
 2 3.8 ± 1.6   
Etiology   0.153  
 Viral 8.5 ± 5.5   
 Non-viral 6.6 ± 5.5   
Child-Pugh class   <0.001 0.026
 A 8.5 ± 7.2   
 B 5.2 ± 1.6   
AFP (ng/ml)   0.890  
  ≤ 400 8.5 ± 6.2   
  > 400 7.2 ± 2.8   
Albumin (g/dL)   0.003 0.076
  ≤ 3.6 6.6 ± 2.8   
  > 3.6 15.2 ± 6.2   
Hemoglobin (g/dL)   0.141  
  ≤ 11 6.6 ± 5.2   
  > 11 9.5 ± 6.2   
PVTT   0.541
 Yes 10.2 ± 5.5   
 No 6.6 ± 4.7   
BED (Gy10)   0.836  
  ≤ 65.5 7.2 ± 5.5   
  > 65.5 15.1 ± 1.6   
RT duration (days)   0.443  
  ≤ 37 8.5 ± 5.5   
  > 37 7.8 ± 2.8   
Tumor response   <0.001 0.016
 Yes 27.8 ± 8.5   
 No 6.2 ± 2.8   
Local control   0.007 0.011
 Yes 13.2 ± 4.8   
 No 7.3 ± 2.6   
  1. PVTT portal vein tumor thrombus, HCC hepatocellular carcinoma, ECOG Eastern Cooperative Oncology Group, BED biologically effective dose, SD standard deviation, AFP Alpha-fetoprotein